BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Memento EPFL//
BEGIN:VEVENT
SUMMARY:U.S. CDMRP – Amyotrophic Lateral Sclerosis Research Program | Re
 search Funding
DTSTART;VALUE=DATE:20260624
DTSTAMP:20260528T052258Z
UID:30c71f4252d88101856b2636b4745753c83e85768e2db58466894f51
CATEGORIES:Call for proposal
DESCRIPTION:Aim: Through the Congressionally Directed Medical Research Pro
 gram (CDMRP)\, the Department of Defense is announcing the 2026 Amyotrophi
 c Lateral Sclerosis Research Program (ALSRP) Awards. Several award program
 s are available:\n\n	The Clinical Outcomes and Biomarkers Award supports t
 he development and/or validation of clinical outcomes and biomarkers to en
 rich clinical trials in Amyotrophic Lateral Sclerosis (ALS). Projects can 
 be relevant to a specific therapy\, a class of therapeutics\, or to a spec
 ific ALS subtype (such as a particular genetic mutation) and do not have t
 o broadly apply to all patients. Applications must address at least one of
  the focus areas listed here.\n	The Pilot Clinical Trial Award supports th
 e rapid implementation of clinical trials with the potential to have a sig
 nificant impact on the treatment or symptom management of ALS. Proposed pr
 ojects may range from phase 1 to small-scale phase 2 trials. Applications 
 must address at least one of the focus areas listed here.\n	The Therapeuti
 c Development Award supports research ranging from preclinical validation 
 of therapeutic leads through FDA IND-enabling studies. The proposed studie
 s are expected to be empirical in nature and product driven. Applicants wi
 th limited ALS experience are strongly encouraged to include collaborators
  with substantial experience in the relevant ALS model systems\, endpoints
 \, and pathophysiology. Candidate therapeutics that already have been gran
 ted an IND are not appropriate for the TDA.\n	The Therapeutic Idea Award s
 upports new\, innovative\, high-risk\, high-gain ideas aimed at ALS drug o
 r therapy discovery. The studies supported by this award mechanism are exp
 ected to be hypothesis-driven and generate preliminary data for future ave
 nues of therapeutic investigation.\n\nFunding:      \n\n\n	Clinical O
 utcomes and Biomarkers Award: max. $1M\n	Pilot Clinical Trial Award: max. 
 $2.8M\n	Therapeutic Development Award: max. $2M\n	Therapeutic Idea Award: 
 max. $840K\n\nNote: Cost caps are total costs (direct plus indirect cost
 s). In accordance with EPFL guidelines\, budgets should include a 20% over
 head\, and the total budget must remain within the grant’s maximum allow
 able funding\n\nDuration:   \n\n\n	Clinical Outcomes and Biomarkers Awar
 d: 3 years\n	Pilot Clinical Trial Award: 3 years\n	Therapeutic Development
  Award: 3 years\n	Therapeutic Idea Award: 2 years\n\nEligibility: Applican
 ts from international organizations or institutions are eligible to apply\
 , and there are no citizenship restrictions. Independent investigators at 
 all career levels are eligible.\n\nHow to Apply: Pre-applications are subm
 itted through the eBRAP platform. They should contain contact information\
 , a letter of intent\, and a list of collaborators and key personnel as su
 ggested on the platform. Full applications will be made via a Grants.gov w
 orkspace.\n\nPre-Application Deadline: 24 June 2026\, 5:00 p.m. Eastern ti
 me\nFull Application Deadline: 30 September 2026\, 11:59 p.m Eastern Time\
 n\nFurther information:\n\n\n	To find the full program announcements and t
 o start your pre-application see here\n	A useful summary of each call can 
 be found here\n	For questions about the eBRAP or Grants.gov platforms\, co
 ntact the Research Office.\n	Grants.gov Funding Opportunity Numbers:\n	\n	
 	Clinical Outcomes and Biomarkers Award: HT942526ALSRPCOBA\n		Pilot Clinic
 al Trial Award: HT942526ALSRPPCTA\n		Therapeutic Development Award : HT94
 2526ALSRPTDA\n		Therapeutic Idea Award: HT942526ALSRPTIA\n	\n	\n
LOCATION:
STATUS:CONFIRMED
END:VEVENT
END:VCALENDAR